NCT05565222View on ClinicalTrials.gov

Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit

PHASE3RecruitingINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

March 11, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions

SepsisSeptic Shock

Interventions

DRUG

Piperacillin/tazobactam or temocillin

"Piperacillin/tazobactam : 4.5 g by intravenous route every 6 hours (adjusted in case of renal failure).~Temocillin : 6g/24 hours infused continuously by intravenous route after 2 g loading dose (adjusted in case of renal failure)"

DRUG

Meropenem

2 g every 8 hours by intravenous route (adjusted in case of renal failure)

Trial Locations (2)

75013

RECRUITING

LUYT Charles -Edouard, Paris

RECRUITING

MAYAUX Julien, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER